Inspira Technologies Sets CVR-Backed Deal Structure for Breast Cancer Liquid Biopsy Expansion

The latest update is out from Inspira Technologies Oxy BHN ( (IINN) ).

On January 8, 2026, Inspira Technologies outlined a strategic vision and proposed transaction framework for expanding into breast cancer liquid biopsy diagnostics through the acquisition of an advanced platform focused on circulating tumor cells, alongside a concurrent $15 million equity investment at a pre-money valuation of $180 million. The deal is structured so that up to 40% of Inspira’s fully diluted share capital would be issued to acquire the liquid biopsy business, while existing shareholders of record before closing would receive contingent value rights (CVRs) designed to ensure they capture future economic benefits from the company’s core respiratory and life-support technologies, including potential dividends and proceeds from any future strategic transactions involving those assets; the company emphasized that its current FDA-cleared ART100 deployments and commercial pipeline remain on track, with up to $12 million of the new capital earmarked to fund and accelerate its ongoing respiratory and blood-monitoring operations, and the parties are targeting definitive agreements within about four weeks of a January 5, 2026 term sheet.

The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.

The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., forming the basis for the next-generation INSPIRA ART500 system aimed at providing oxygenation to awake, spontaneously breathing patients. The company is also developing HYLA, a proprietary continuous, non-invasive blood sensor platform, and is positioning itself as an integrated life-support and MedTech platform with a growing IP portfolio and streamlined operations.

Average Trading Volume: 190,619

Technical Sentiment Signal: Strong Sell

Current Market Cap: $33.61M

See more insights into IINN stock on TipRanks’ Stock Analysis page.